{"id":8739,"date":"2020-03-24T17:08:20","date_gmt":"2020-03-24T11:38:20","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8739"},"modified":"2021-07-24T12:57:50","modified_gmt":"2021-07-24T07:27:50","slug":"recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher","title":{"rendered":"Thermo\u2019s investment; Biohaven\u2019s vazegepant Phase III trial; Cumberland\u2019s aid"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services.<\/strong><\/h2>\n\n\n\n<p>The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020.&nbsp;<\/p>\n\n\n\n<p>The company has been acquiring several companies to fulfil its goal of providing valuable healthcare and ensure there is no shortage of medicines to patients. Recently, Thermo Fischer has acquired Qiagen NV- a Netherlands based pharma company, which was currently focused on developing a vaccine for <a href=\"https:\/\/www.delveinsight.com\/blog\/questions-and-answers-on-coronavirus-covid-19\/\">COVID-19<\/a>. The company, the last year, had also bought a CDMO \u2013 Brammer Biomanufacturingng viral vectors for gene\/ cell therapies.&nbsp;<\/p>\n\n\n\n<p>The company has managed to double the production capacity of biological drugs and their commercial manufacturing, with the launch of new bioprocessing centres on the horizon.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Biohaven Pharma has decided to carry forward the trails of<\/strong> <strong>intranasal vazegepant to Phase III for the treatment of acute migraine.&nbsp;<\/strong><\/h2>\n\n\n\n<p>Vazegepant (BHV-3500), is a highly soluble CGRP (Calcitonin gene-related peptide) receptor antagonist, distinct from its other candidate in CGRP platform \u2013 rimegepant. The decision to advance the evaluation into Phase III came after a successful end-of-phase meeting with the FDA.&nbsp;<\/p>\n\n\n\n<p>The results from Phase II\/III revealed 10mg and 20 mg doses of the drug proved superior to placebo on the co-primary endpoints of pain freedom and freedom from most bothersome symptoms of photophobia, phonophobia and nausea at two hours following a single dose.<\/p>\n\n\n\n<p>If gets approved, <strong>vazegepant <\/strong>will be available in the market along with its other complementary candidate of the company, <strong>rimegepant<\/strong>, which has recently been approved for the acute treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/migraine-market\">migraine <\/a>in adults.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Cumberland Pharmaceuticals has announced to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia associated with the outbreak of the COVID-19 coronavirus.<\/strong><\/h2>\n\n\n\n<p>The company is planning to support the treatment by offering financial arrangements, including extended payment for all direct account purchase of VIBATIV antibiotic. Moreover, the company also plans to provide flexible healthcare facilities, potent antibiotic treatments, supporting the increasing demand.&nbsp;<\/p>\n\n\n\n<p>The company is helping hospitals and clinics ensuring sufficiently supply of drugs and therapies in the time of <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\/\">COVID-19<\/a> crisis.&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/pneumonia-pneumococcal-market\">Pneumonia <\/a>\u2013 caused by secondary bacterial infections- is a common sight in patients with viral respiratory infections, with 1.3 million people in the US reported seeking care due to <a href=\"https:\/\/www.delveinsight.com\/report-store\/pneumonia-epidemiology-forecast\">pneumonia <\/a>in 2017, as per National Hospital Ambulatory Medical Care Survey 2017. <br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services. The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020.&nbsp; The company has been acquiring several companies to fulfil its goal of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8740,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18152,10830,349,639,4502,5789,1194,18151,18153],"industry":[17225],"therapeutic_areas":[17231,17243],"class_list":["post-8739","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biohaven-pharma","tag-covid-19","tag-latest-pharma-news","tag-pharma-news","tag-pneumonia","tag-recent-pharma-news","tag-rimegepant","tag-thermo-fisher-scientific","tag-vazegepant","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Thermo\u2019s investment; Vazegepant Phase III trial; Cumberland\u2019s aid<\/title>\n<meta name=\"description\" content=\"Vazegepant (BHV-3500), is a highly soluble CGRP receptor antagonist, distinct from its other candidate in CGRP platform \u2013 rimegepant..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Thermo\u2019s investment; Vazegepant Phase III trial; Cumberland\u2019s aid\" \/>\n<meta property=\"og:description\" content=\"Vazegepant (BHV-3500), is a highly soluble CGRP receptor antagonist, distinct from its other candidate in CGRP platform \u2013 rimegepant..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-24T11:38:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/24170032\/Pharma-News-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Thermo\u2019s investment; Vazegepant Phase III trial; Cumberland\u2019s aid","description":"Vazegepant (BHV-3500), is a highly soluble CGRP receptor antagonist, distinct from its other candidate in CGRP platform \u2013 rimegepant..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher","og_locale":"en_US","og_type":"article","og_title":"Thermo\u2019s investment; Vazegepant Phase III trial; Cumberland\u2019s aid","og_description":"Vazegepant (BHV-3500), is a highly soluble CGRP receptor antagonist, distinct from its other candidate in CGRP platform \u2013 rimegepant..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-03-24T11:38:20+00:00","article_modified_time":"2021-07-24T07:27:50+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/24170032\/Pharma-News-2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher","name":"Thermo\u2019s investment; Vazegepant Phase III trial; Cumberland\u2019s aid","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/24170032\/Pharma-News-2.jpg","datePublished":"2020-03-24T11:38:20+00:00","dateModified":"2021-07-24T07:27:50+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Vazegepant (BHV-3500), is a highly soluble CGRP receptor antagonist, distinct from its other candidate in CGRP platform \u2013 rimegepant..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-biohaven-cumberland-pharma-thermo-fisher#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/24170032\/Pharma-News-2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/24170032\/Pharma-News-2.jpg","width":772,"height":482,"caption":"Pharma-News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/24170032\/Pharma-News-2-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biohaven Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pneumonia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rimegepant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Thermo Fisher Scientific<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vazegepant<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biohaven Pharma<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pneumonia<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Rimegepant<\/span>","<span class=\"advgb-post-tax-term\">Thermo Fisher Scientific<\/span>","<span class=\"advgb-post-tax-term\">Vazegepant<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 24, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 24, 2020 5:08 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma-News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8739"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8739\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8740"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8739"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8739"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}